Breakdown of the capital invested by primary industry code, a system of classification indicative of a business's main line of revenue, shows that as expected biotechnology, pharmaceuticals and drug discovery, together account for almost 90% of capital invested (Figure ). Other industries with smaller contributions include agricultural chemicals, diagnostic equipment and laboratory services among others (Figure ). This is in line with our analysis which also identified CRISPR therapeutics and CRISPR in agriculture as the major applications. Time trends of capital invested in these sectors indicate largest influx of capital in the biotechnology industry with two major spikes in 2019 and 2021. A record number of deals occurred in 2021 and few of the biggest (in terms of deal size) involved Century Therapeutics and Mammoth Biosciences (>150M USD) and, Caribou Biosciences and AgBiome (>100M USD). The most consistent influx in capital on the other hand appears to be in drug discovery until 2021 with a plunge in 2022 and uptick again after 2022 (Figure ).